# Cresilon

> Cresilon is a Brooklyn medical-device manufacturer turning a flowable, plant-derived polymer gel into products for bleeding control. Its VETIGEL line serves veterinary surgeons, while FDA-cleared TRAUMAGEL is sold to licensed medical professionals for temporary control of moderate to severe external bleeding. The company makes the gel in-house, sells through direct and distribution channels, and competes with gauze, tourniquets, powders and other topical hemostatic products.

- **Founded:** 2010
- **Headquarters:** Brooklyn, United States
- **Founders:** Joe Landolina (CEO and Co-founder), Isaac Miller (EVP and Co-founder)
- **Team size:** More than 100 employees reported by the company in April 2026; LinkedIn lists 51-200.
- **Products:** VETIGEL, Cresilon Hemostatic Gel (CHG), TRAUMAGEL, TRAUMAGEL 2.0
- **Notable:** Won NYU's InnoVention Competition roots with the founding team in 2010., Built GMP manufacturing capacity in Brooklyn after contract manufacturing and testing proved inadequate., Received FDA 510(k) clearance for Cresilon Hemostatic Gel in June 2023.

## Products & services

- **VETIGEL** — A ready-to-use, flowable hemostatic gel in a prefilled syringe for veterinary surgical and traumatic bleeding; its polymers are non-animal-derived.
- **Cresilon Hemostatic Gel (CHG)** — FDA-cleared hemostatic gel for local management of bleeding wounds such as minor cuts, lacerations and abrasions.
- **TRAUMAGEL** — A single-use 30 mL hemostatic gel for licensed medical professionals to temporarily control moderate to severe external bleeding.
- **TRAUMAGEL 2.0** — An updated FDA-cleared presentation whose gel composition, indication and mechanism remain unchanged from TRAUMAGEL.

## Achievements

- Won NYU's InnoVention Competition roots with the founding team in 2010.
- Built GMP manufacturing capacity in Brooklyn after contract manufacturing and testing proved inadequate.
- Received FDA 510(k) clearance for Cresilon Hemostatic Gel in June 2023.
- Ranked No. 1 in Fast Company's medical devices category in 2024.
- Received FDA 510(k) clearance for TRAUMAGEL in August 2024.
- Launched TRAUMAGEL nationally in January 2025.
- Reported adoption by more than 150 EMS agencies by July 2026.
- Published human case reports and a three-case tourniquet-conversion series in peer-reviewed journals in 2025-2026.
- Ranked No. 1 in Fast Company's medical devices category and No. 46 overall in 2026.

## Latest updates

- **2025-01** — TRAUMAGEL launched nationwide in the United States; Zomedica announced its VETIGEL license and supply agreement.
- **2025-06** — McCarthy Vet became VETIGEL's Canadian distributor.
- **2025-11** — A peer-reviewed case report described EMS use of TRAUMAGEL on a complex scalp laceration after traditional measures failed.
- **2026-03** — Vizient awarded TRAUMAGEL an Innovative Technology contract; Fast Company ranked Cresilon No. 1 in medical devices and No. 46 overall.
- **2026-06** — FDA records show clearance documentation for TRAUMAGEL 2.0, with unchanged indication, composition and mechanism.
- **2026-07** — A peer-reviewed three-case series reported hemorrhage control and tourniquet removal without rebleeding; Cresilon reported use by more than 150 EMS agencies.

## Links

- Website: https://cresilon.com/
- LinkedIn: https://www.linkedin.com/company/cresilon/
- Twitter/X: https://x.com/Cresilon
- YouTube: https://www.youtube.com/channel/UCeScpOPVf0oGXBamAzuh14Q/featured
- Instagram: https://www.instagram.com/cresilon_us/
- Facebook: https://www.facebook.com/cresilon/

---

Profile page: https://yespress.io/cresilon
Published by YesPress — https://yespress.io
Last updated: 2026-08-22